RHS is a developer of sophisticated novel molecular tools for amplifying DNA and determining the genetic contents of a single cell.
Published clinical studies have shown that a primary reason for IVF failure is the embryo having the wrong number of chromosomes, which is known as aneuploidy. One of the most significant recent advances to improve IVF success rates has been the introduction of advanced Pre-implantation Genetic Screening (PGS), where embryos are screened to determine whether they have the correct number of chromosomes before being selected for IVF transfer.
Specifically developed to offer an integrated, easy to use and interpret, price competitive product, RHS’s EmbryoCellect™ is a Pre-implantation Genetic Screening kit designed to increase the chance of a successful IVF cycle.
RHS recently listed on the Australian Stock Exchange (ASX:RHS). Prior to its listing, the company received over $1 million in grants from both the Australian and South Australian Governments and raised $5.5 million in venture capital investment.
COOE delivers practical and sustainable solutions in environmental science and engineering to industry and governments.Read More
RHS develops sophisticated novel molecular tools for amplifying DNA and determining the genetic contents of a single cell.Read More
GeneWorks Pty Ltd is a quality-certified genomics technology supplier to the bio-research community.Read More
Ziltek provides remediation solutions for environmental consultants, contractors, landowners, industry and government agencies.Read More